Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | K-756 |
Synonyms | |
Therapy Description |
K-756 inhibits tankyrase, resulting in decreased Wnt/beta-catenin pathway signaling, and potentially leading to decreased tumor cell growth in combination with other agents (PMID: 27196752). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
K-756 | Tankyrase Inhibitor 11 | K-756 inhibits tankyrase, resulting in decreased Wnt/beta-catenin pathway signaling, and potentially leading to decreased tumor cell growth in combination with other agents (PMID: 27196752). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC mutant | colorectal cancer | predicted - sensitive | K-756 | Preclinical | Actionable | In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752). | 27196752 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|